Could a common antibiotic help calm dangerous IPF Flare-Ups?

NCT ID NCT05842681

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the antibiotic azithromycin to standard treatment helps people with idiopathic pulmonary fibrosis (IPF) recover faster from sudden, severe flare-ups. Researchers will compare hospital stay length and other outcomes between those who get azithromycin plus usual care and those who get usual care alone. About 1000 participants are being enrolled at Assiut University.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
azithromycin
What this could lead to
If it works, adding azithromycin could become a standard way to treat sudden worsening of IPF, potentially shortening hospital stays and improving recovery.
What could go wrong
This is an early-stage trial with no phase designation, and the results may not apply to all IPF patients. Azithromycin can cause side effects like stomach upset or heart rhythm issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Assiut university-Faculty of Medicine

    RECRUITING

    Asyut, 71515, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Faculty of Medicine Assuit University

    ACTIVE_NOT_RECRUITING

    Asyut, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.